Cargando…

A single-arm phase II study of olaparib maintenance with pembrolizumab and bevacizumab in BRCA non-mutated patients with platinum-sensitive recurrent ovarian cancer (OPEB-01)

BACKGROUND: The optimal treatment of BRCA wild-type patients with platinum-sensitive recurrent ovarian cancer remains unknown. Recently, there is an increase in the evidence to support the role of the combination of a poly(adenosine diphosphate-ribose) polymerase inhibitor, anti-angiogenic agents, a...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lee, Yong Jae, Lim, Myong Cheol, Kim, Byoung-Gie, Ngoi, Natalie YL, Choi, Chel Hun, Park, Sang-Yoon, Tan, David SP, Go, Yunjung, Lee, Jung-Yun
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Asian Society of Gynecologic Oncology; Korean Society of Gynecologic Oncology; Japan Society of Gynecologic Oncology 2021
Materias:	Clinical Trial Protocol
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7930449/ https://www.ncbi.nlm.nih.gov/pubmed/33559413 http://dx.doi.org/10.3802/jgo.2021.32.e31

Ejemplares similares

Triplet maintenance therapy of olaparib, pembrolizumab and bevacizumab in women with BRCA wild-type, platinum-sensitive recurrent ovarian cancer: the multicenter, single-arm phase II study OPEB-01/APGOT-OV4
por: Kim, Yoo-Na, et al.
Publicado: (2023)

A single-arm, phase II study of niraparib and bevacizumab maintenance therapy in platinum-sensitive, recurrent ovarian cancer patients previously treated with a PARP inhibitor: Korean Gynecologic Oncology Group (KGOG 3056)/NIRVANA-R trial
por: Park, Junsik, et al.
Publicado: (2021)

Cediranib in Combination with Olaparib in Patients without a Germline BRCA1/2 Mutation and with Recurrent Platinum-Resistant Ovarian Cancer: Phase IIb CONCERTO Trial
por: Lee, Jung-Min, et al.
Publicado: (2022)

Real-World Experience of Olaparib Maintenance in High-Grade Serous Recurrent Ovarian Cancer Patients with BRCA1/2 Mutation: A Korean Multicenter Study
por: Paik, E Sun, et al.
Publicado: (2019)

Clinical Activity and Safety of Cediranib and Olaparib Combination in Patients with Metastatic Pancreatic Ductal Adenocarcinoma without BRCA Mutation
por: Kim, Joseph W., et al.
Publicado: (2021)

Comparisons of survival outcomes between bevacizumab and olaparib in BRCA-mutated, platinum-sensitive relapsed ovarian cancer: a Korean Gynecologic Oncology Group study (KGOG 3052)
por: Kim, Se Ik, et al.
Publicado: (2021)

A phase II study of neoadjuvant chemotherapy plus durvalumab and tremelimumab in advanced-stage ovarian cancer: a Korean Gynecologic Oncology Group Study (KGOG 3046), TRU-D
por: Lee, Jung-Yun, et al.
Publicado: (2019)

Olaparib Efficacy in Patients with Metastatic Castration-resistant Prostate Cancer and BRCA1, BRCA2, or ATM Alterations Identified by Testing Circulating Tumor DNA
por: Matsubara, Nobuaki, et al.
Publicado: (2023)

Case Report: Sustained complete remission on combination therapy with olaparib and pembrolizumab in BRCA2-mutated and PD-L1-positive metastatic cholangiocarcinoma after platinum derivate
por: Zhou, Taotao, et al.
Publicado: (2022)

Olaparib and somatic BRCA mutations
por: George, Angela, et al.
Publicado: (2017)

Olaparib Maintenance Monotherapy in Asian Patients with Platinum-Sensitive Relapsed Ovarian Cancer: Phase III Trial (L-MOCA)
por: Gao, Qinglei, et al.
Publicado: (2022)

A multicenter phase II randomized trial of durvalumab (MEDI-4736) versus physician’s choice chemotherapy in recurrent ovarian clear cell adenocarcinoma (MOCCA)
por: Ngoi, Natalie YL, et al.
Publicado: (2020)

Low-dose-intensity bevacizumab with weekly irinotecan for platinum- and taxanes-resistant epithelial ovarian cancer
por: Liu, Ying, et al.
Publicado: (2015)

GEICO1601-ROLANDO: a multicentric single arm Phase II clinical trial to evaluate the combination of olaparib and pegylated liposomal doxorubicin for platinum-resistant ovarian cancer
por: Perez-Fidalgo, J Alejandro, et al.
Publicado: (2019)

Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients with BRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore
por: Tan, David SP, et al.
Publicado: (2021)

Beyond BRCA Status: Clinical Biomarkers May Predict Therapeutic Effects of Olaparib in Platinum-Sensitive Ovarian Cancer Recurrence
por: Nakanishi, Kazuho, et al.
Publicado: (2021)

Immunohistochemistry study of tumor vascular normalization and anti-angiogenic effects of sunitinib versus bevacizumab prior to dose-dense doxorubicin/cyclophosphamide chemotherapy in HER2-negative breast cancer
por: Yadav, Kritika, et al.
Publicado: (2021)

Olaparib and Pembrolizumab Treatment for BRCA1-Mutated and PD-L1-Positive Intrahepatic Cholangiocarcinoma Recurrence and Metastasis: A Case Report
por: Xiong, Fan, et al.
Publicado: (2020)

Primary malignant melanoma of the uterine cervix treated with pembrolizumab after radical surgery: a case report and literature review
por: Kim, Myeong Seon, et al.
Publicado: (2018)

Phase 3, randomized, open-label study of pembrolizumab plus lenvatinib versus chemotherapy for first-line treatment of advanced or recurrent endometrial cancer: ENGOT-en9/LEAP-001
por: Marth, Christian, et al.
Publicado: (2022)

Pembrolizumab Plus Pemetrexed and Platinum in Nonsquamous Non–Small-Cell Lung Cancer: 5-Year Outcomes From the Phase 3 KEYNOTE-189 Study
por: Garassino, Marina C., et al.
Publicado: (2023)

Exceptional Response to Olaparib and Pembrolizumab for Pancreatic Adenocarcinoma With Germline BRCA1 Mutation and High Tumor Mutation Burden: Case Report and Literature Review
por: Lundy, Joanne, et al.
Publicado: (2022)

Relevance of Platinum-free Interval and BRCA Reversion Mutations for Veliparib Monotherapy after Progression on Carboplatin/Paclitaxel for gBRCA Advanced Breast Cancer (BROCADE3 Crossover)
por: Puhalla, Shannon L., et al.
Publicado: (2021)

Olaparib Outcomes in Patients with BRCA 1-2 Mutated, Platinum-Sensitive, Recurrent Ovarian Cancer in Croatia: A Retrospective Noninterventional Study
por: Majić, Ana, et al.
Publicado: (2020)

A narrative review of Safety management of 1 L platinum-based chemotherapy and maintenance olaparib in BRCA mutated advanced pancreatic cancer
por: Yao, Jiayu, et al.
Publicado: (2021)

The 4th European Society for Medical Oncology Asia Congress: bridging ultimate cancer care with real-world practice for the Asian practitioner in gynecological cancers
por: Ngoi, Natalie YL, et al.
Publicado: (2019)

ATARI trial: ATR inhibitor in combination with olaparib in gynecological cancers with ARID1A loss or no loss (ENGOT/GYN1/NCRI)
por: Banerjee, Susana, et al.
Publicado: (2021)

Prevalence and clinical characterization of BRCA1 and BRCA2 mutations in Korean patients with epithelial ovarian cancer
por: Paik, E Sun, et al.
Publicado: (2021)

Olaparib treatment for BRCA-mutant ovarian cancer with leptomeningeal disease
por: Bangham, Madeleine, et al.
Publicado: (2016)

Zebrafish Xenografts Unveil Sensitivity to Olaparib beyond BRCA Status
por: Varanda, Ana Beatriz, et al.
Publicado: (2020)

A phase I, randomized, single-dose pharmacokinetic study comparing sb8 (bevacizumab biosimilar) with reference bevacizumab in healthy volunteers
por: Shin, Donghoon, et al.
Publicado: (2020)

Complete pathological response to olaparib and bevacizumab in advanced cervical cancer following chemoradiation in a BRCA1 mutation carrier: a case report
por: Montero-Macias, Rosa, et al.
Publicado: (2021)

Efficacy and safety of olaparib maintenance therapy in platinum-sensitive ovarian cancer patients with BRCA mutations: a meta-analysis on randomized controlled trials
por: Ma, Jiao, et al.
Publicado: (2019)

Cost-effectiveness analysis of olaparib as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1/2 mutation in china
por: Shu, Yamin, et al.
Publicado: (2022)

Olaparib as maintenance treatment for patients with platinum-sensitive relapsed ovarian cancer
por: Ledermann, Jonathan A., et al.
Publicado: (2019)

Systematic Review of Olaparib in the Treatment of Recurrent Platinum Sensitive Ovarian Cancer
por: Chen, Qian, et al.
Publicado: (2022)

BRCA2 reversion mutation confers resistance to olaparib in breast cancer
por: Yamamoto, Shinya, et al.
Publicado: (2023)

Olaparib in combination with pegylated liposomal doxorubicin for platinum-resistant ovarian cancer regardless of BRCA status: a GEICO phase II trial (ROLANDO study)
por: Perez-Fidalgo, J.A., et al.
Publicado: (2021)

Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status Phase II LIGHT study primary analysis
por: Cadoo, Karen, et al.
Publicado: (2022)

Olaparib is effective for recurrent urothelial carcinoma with BRCA2 pathogenic germline mutation: first report on olaparib response in recurrent UC
por: Yang, Hong, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_dfer8m9l0hmmuudho0kiiggfp0